37 results
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
and strategy to provide context for the remainder of the MD&A.
Results of Operations – Analysis of our financial results comparing the three months
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
be for any full fiscal year or future period.
Our MD&A is organized as follows:
Company Overview – Discussion of our business plan and strategy
8-K
EX-99.1
BIAF
BioAffinity Technologies Inc
15 May 24
Results of Operations and Financial Condition
6:07pm
strategy, moving beyond the initial test market in Texas, the unique and compelling attributes of CyPath® Lung, including its AI-enhanced data … to advance the Company’s commercial strategy, moving beyond the initial test market in Texas, positioning CyPath® Lung to set a new standard in the early
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
Should the FDA disagree that CyPath® Lung is an LDT our commercialization strategy may be adversely affected.
FDA failure to grant our request for de … to implement our growth strategy. As a result, adequate capital may not be available to finance our current development plan, take advantage
POS AM
ng0ns6h93z3e xqy
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
424B5
aux qte1ag5b
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
fnuqygobgd2pex1y
7 Mar 24
Prospectus supplement for primary offering
9:57pm
424B5
owv4thkg k7a1hm7bw4q
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
7vf2k pmh6ym
16 Nov 23
Shelf registration
5:23pm
8-K
EX-99.1
j3dpwnn
15 Nov 23
Results of Operations and Financial Condition
5:07pm
8-K
EX-99.2
jsoa35zu bk38fl9yyg
10 Oct 23
Regulation FD Disclosure
5:27pm
8-K
EX-99.1
d2l5nsinzri
14 Aug 23
Results of Operations and Financial Condition
4:28pm